세계의 약물감시 시장 규모, 점유율, 동향 분석 보고서 : 제품수명주기별, 서비스 프로바이더별, 종류별, 치료 분야별, 프로세스 플로우별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Pharmacovigilance Market Growth & Trends:

The global pharmacovigilance market size is projected to reach USD 11.78 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to witness growth at a CAGR of 6.5% from 2025 to 2030. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundacao Instituto de Pesquisas Farmaceuticas) and Pharmacy College (Universidade de Sao Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed's earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights:

• Phase IV dominated the market with a revenue share of over 75.90% in 2024. This was driven by increased ADR incidents and post-marketing surveillance
• contract outsourcing segment held the largest market share in in the service provider segment in 2024, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
• Spontaneous reporting segment dominated the pharmacovigilance market in 2024 with the largest share. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
• Oncology held the largest share of over 27.14% in the therapeutic area segment in 2024, fueled by biopharmaceutical companies' research efforts in chronic cancer treatments
• Case data management is anticipated to grow at the fastest CAGR in the process flow segment during the forecast period
• The biotechnology companies segment is expected to grow at the fastest CAGR during the forecast period. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
• North America held the largest revenue share of over 32.11% in 2024 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
• Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Life Cycle
  • 1.2.2. Service Provider
  • 1.2.3. Type
  • 1.2.4. Process Flow
  • 1.2.5. Therapeutic area
  • 1.2.6. End use
  • 1.2.7. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
    • 1.5.4.1. Details of Primary Research
    • 1.5.4.2. Data for primary interviews in North America
    • 1.5.4.3. Data for Primary Interviews in Europe
    • 1.5.4.4. Data for Primary Interviews in APAC
    • 1.5.4.5. Data for Primary Interviews in Latin America
    • 1.5.4.6. Data for Primary Interviews in MEA
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Report Objectives
  • 1.10.1. Objective-1
  • 1.10.2. Objective-2

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
  • 2.2.1. Segment Snapshot (Product Life Cycle & Type)
  • 2.2.2. Segment Snapshot (Process Flow & Therapeutic Area)
  • 2.2.3. Segment Snapshot (End Use)
  • 2.2.4. Competitive Landscape Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing drug consumption and drug development rates
    • 3.2.1.2. Increasing incidence of ADR and drug toxicity
    • 3.2.1.3. Increasing trend of outsourcing pharmacovigilance services
    • 3.2.1.4. Increasing externalization of clinical trial studies by large
    • 3.2.1.5. Increasing Regulatory Burden on Manufacturers
    • 3.2.1.6. Introduction of technologically advanced software services
      • 3.2.1.6.1. Key focus areas for the pharmaceutical/healthcare companies
      • 3.2.1.6.2. Adoption of technological advancements in Life sciences industry
      • 3.2.1.6.3. Published Survey insights - related to adoption of pharmacovigilance automation
    • 3.2.1.7. Rising investment on R&D by healthcare companies
    • 3.2.1.8. Partnerships and collaborations between market players
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Shortage of skilled labor
    • 3.2.2.2. Expensive technology for small and mid-sized player
    • 3.2.2.3. Lack of recognition
    • 3.2.2.4. Scarcity of integration standards
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Supplier power
  • 3.3.2. Buyer power
  • 3.3.3. Substitution threat
  • 3.3.4. Threat of new entrant
  • 3.3.5. Competitive rivalry
• 3.4. PESTLE Analysis
• 3.5. Value Chain Analysis
  • 3.5.1. Preclinical
  • 3.5.2. Clinical
  • 3.5.3. PMA
• 3.6. Mapping of Life Cycle Against Service Offering and Their Demand
• 3.7. Regulatory Framework
  • 3.7.1. List of regulatory bodies by Country
• 3.8. Pricing Models
  • 3.8.1. Drug safety budget allocation by activities
  • 3.8.2. By development phase
  • 3.8.3. By therapeutic area
  • 3.8.4. Pricing level
    • 3.8.4.1. Project management
    • 3.8.4.2. Case processing
    • 3.8.4.3. ADR Reporting
    • 3.8.4.4. Medical writing
    • 3.8.4.5. Drug safety management
• 3.9. Technology Timeline Overview
  • 3.9.1. Changing Technology & Adoption
  • 3.9.2. Current Technology Landscape of PV
  • 3.9.3. IQVIA's AI-Driven Transformation in Pharmacovigilance
  • 3.9.4. Tech Mahindra's AI-Driven Pharmacovigilance Solution in
  • 3.9.5. The evolving PV workload with AI assistance
  • 3.9.6. Social Media
    • 3.9.6.1. Literature screening
    • 3.9.6.2. Automation and AI
    • 3.9.6.3. Big data analytics in PV
• 3.10. COVID 19 Impact Analysis
  • 3.10.1. Developments & Strategic Outcomes
    • 3.10.1.1. Regulatory requirements/changes due to covid-19
    • 3.10.1.2. Strategies implemented by companies
      • 3.10.1.2.1. IQVIA
      • 3.10.1.2.2. IBM Corporation
      • 3.10.1.2.3. ArisGlobal
      • 3.10.1.2.4. PAREXEL International Corporation
      • 3.10.1.2.5. Bioclinica
      • 3.10.1.2.6. Pharmaceutical Product Development (PPD)
      • 3.10.1.2.7. ICON, plc
      • 3.10.1.2.8. PRA Health Sciences
      • 3.10.1.2.9. Linical Accelovance
      • 3.10.1.2.10. Laboratory Corporation of America Holdings
• 3.11. Market Trend:
  • 3.11.1. Scaling of resources
  • 3.11.2. Automation in Pharmacovigilance
• 3.12. Impact of Inflation
• 3.13. Case Studies
  • 3.13.1. Potential Customers
  • 3.13.2. Notable Use Cases
  • 3.13.3. Case Study 1
    • 3.13.3.1. Part 1
    • 3.13.3.2. Part 2
  • 3.13.4. Case Study 2
  • 3.13.5. Case Study 3
  • 3.13.6. Case Study 4

Chapter 4. Pharmacovigilance Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Product Market Share Movement Analysis, 2024 & 2030
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.3.1. Preclinical
    • 4.3.1.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Phase I
    • 4.3.2.1. Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Phase II
    • 4.3.3.1. Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.4. Phase III
    • 4.3.4.1. Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.5. Phase IV
    • 4.3.5.1. Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

• 5.1. Service Provider Dashboard
• 5.2. Service Provider Market Share Movement Analysis, 2024 & 2030
• 5.3. Market Size & Forecasts and Trend Analysis, by Service Provider, 2018 to 2030 (USD Million)
• 5.4. In House
  • 5.4.1. In-house market, 2018 - 2030 (USD Million)
• 5.5. Contract Outsourcing
  • 5.5.1. Contract Outsourcing market, 2018 - 2030 (USD Million)

Chapter 6. Pharmacovigilance Market: Type Estimates & Trend Analysis

• 6.1. Type Segment Dashboard
• 6.2. Type Market Share Movement Analysis, 2024 & 2030
• 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 6.4. Spontaneous Reporting
  • 6.4.1. Spontaneous Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Intensified ADR Reporting
  • 6.5.1. Intensified ADR Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Targeted Spontaneous Reporting
  • 6.6.1. Targeted spontaneous reporting market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. Cohort Event Monitoring (CEM)
  • 6.7.1. CEM market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.8. EHR Mining
  • 6.8.1. EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

• 7.1. Process Flow Segment Dashboard
• 7.2. Process Flow Market Share Movement Analysis, 2024 & 2030
• 7.3. Market Size & Forecasts and Trend Analysis, by Process Flow, 2018 to 2030 (USD Million)
• 7.4. Case data management
  • 7.4.1. Case data management market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.1.1. Case logging
      • 7.4.1.1.1. Case logging market, 2018 - 2030 (USD Million)
    • 7.4.1.2. Case data analysis
      • 7.4.1.2.1. Case data analysis market, 2018 - 2030 (USD Million)
    • 7.4.1.3. Medical reviewing and reporting
      • 7.4.1.3.1. Medical reviewing and reporting market, 2018 - 2030 (USD Million)
• 7.5. Signal detection
  • 7.5.1. Signal detection market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.1.1. Adverse Event Logging
      • 7.5.1.1.1. Adverse event logging market, 2018 - 2030 (USD Million)
    • 7.5.1.2. Adverse Event Analysis
      • 7.5.1.2.1. Adverse Event Analysis market, 2018 - 2030 (USD Million)
    • 7.5.1.3. Adverse Event Review & Reporting
      • 7.5.1.3.1. Adverse Event Review & Reporting market, 2018 - 2030 (USD Million)
• 7.6. Risk Management System
  • 7.6.1. Risk Management System market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.1.1. Risk Evaluation System
      • 7.6.1.1.1. Risk Evaluation market, 2018 - 2030 (USD Million)
    • 7.6.1.2. Risk Mitigation System
      • 7.6.1.2.1. Risk Mitigation market, 2018 - 2030 (USD Million)

Chapter 8. Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

• 8.1. Therapeutic Area Segment Dashboard
• 8.2. Therapeutic Area Market Share Movement Analysis, 2024 & 2030
• 8.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 8.4. Oncology
  • 8.4.1. Oncology market, 2018 - 2030 (USD Million)
• 8.5. Neurology
  • 8.5.1. Neurology market, 2018 - 2030 (USD Million)
• 8.6. Respiratory Systems
  • 8.6.1. Respiratory Systems market, 2018 - 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Other market, 2018 - 2030 (USD Million)
• 8.8. Neurology

Chapter 9. Pharmacovigilance Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Regional Market: Key Takeaways
• 9.3. North America
  • 9.3.1. North America Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamic
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive insights
    • 9.3.2.4. U.S. Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamic
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive insights
    • 9.3.3.4. Canada Pharmacovigilance market estimates and forecasts, 2018 - 2030
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamic
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Competitive insights
    • 9.3.4.4. Mexico Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamic
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive insights
    • 9.4.2.4. Germany Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. UK
    • 9.4.3.1. Key country dynamic
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive insights
    • 9.4.3.4. UK Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamic
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive insights
    • 9.4.4.4. France Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamic
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive insights
    • 9.4.5.4. Italy Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamic
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive insights
    • 9.4.6.4. Spain Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.7. Russia
    • 9.4.7.1. Key country dynamic
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive insights
    • 9.4.7.4. Russia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamic
    • 9.4.8.2. Regulatory framework
    • 9.4.8.3. Competitive insights
    • 9.4.8.4. Denmark Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.9. Sweden
    • 9.4.9.1. Key country dynamic
    • 9.4.9.2. Regulatory framework
    • 9.4.9.3. Competitive insights
    • 9.4.9.4. Sweden Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.10. Norway
    • 9.4.10.1. Key country dynamic
    • 9.4.10.2. Regulatory framework
    • 9.4.10.3. Competitive insights
    • 9.4.10.4. Norway Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key country dynamic
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive insights
    • 9.5.2.4. Japan Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key country dynamic
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive insights
    • 9.5.3.4. China Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key country dynamic
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive insights
    • 9.5.4.4. India Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamic
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive insights
    • 9.5.5.4. South Korea Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.6. Australia
    • 9.5.6.1. Key country dynamic
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive insights
    • 9.5.6.4. Australia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.7. Thailand
    • 9.5.7.1. Key country dynamic
    • 9.5.7.2. Regulatory framework
    • 9.5.7.3. Competitive insights
    • 9.5.7.4. Thailand Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key country dynamic
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive insights
    • 9.6.2.4. Brazil Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.6.2.5. (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamic
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive insights
    • 9.6.3.4. Argentina Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key country dynamic
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive insights
    • 9.7.2.4. South Africa Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key country dynamic
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive insights
    • 9.7.3.4. Saudi Arabia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key country dynamic
    • 9.7.4.2. Regulatory framework
    • 9.7.4.3. Competitive insights
    • 9.7.4.4. UAE Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key country dynamic
    • 9.7.5.2. Regulatory framework
    • 9.7.5.3. Competitive insights
    • 9.7.5.4. Kuwait Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Pharmacovigilance Market: Competitive Analysis

• 10.1. Market Participant Categorization
• 10.2. Public Companies
  • 10.2.1. Company Market Position Analysis
  • 10.2.2. Company Market Share Analysis
• 10.3. Competitive Factors and Strategies
  • 10.3.1. Increasing Strategic Collaborations and Product Launches
  • 10.3.2. Strategic Government initiatives, including collaborations
  • 10.3.3. Competitors increased PV Awareness programs
  • 10.3.4. Competitors increased collaboration and outsourcing of operations
  • 10.3.5. Consolidation Trends

Chapter 11. Competitive Landscape

• 11.1. Company Profiles
  • 11.1.1. Accenture
    • 11.1.1.1. Overview
    • 11.1.1.2. Financial performance
    • 11.1.1.3. Product benchmarking
    • 11.1.1.4. Strategic initiatives
  • 11.1.2. IQVIA Inc.
    • 11.1.2.1. Overview
    • 11.1.2.2. Financial performance
    • 11.1.2.3. Product benchmarking
    • 11.1.2.4. Strategic initiatives
  • 11.1.3. Cognizant
    • 11.1.3.1. Overview
    • 11.1.3.2. Financial performance
    • 11.1.3.3. Product benchmarking
    • 11.1.3.4. Strategic initiatives
  • 11.1.4. Clinquest Group B.V. (Linical Americas)
    • 11.1.4.1. Overview
    • 11.1.4.2. Financial performance
    • 11.1.4.3. Product benchmarking
    • 11.1.4.4. Strategic initiatives
  • 11.1.5. IBM
    • 11.1.5.1. Overview
    • 11.1.5.2. Financial performance
    • 11.1.5.3. Product benchmarking
    • 11.1.5.4. Strategic initiatives
  • 11.1.6. Laboratory Corporation of America Holdings
    • 11.1.6.1. Overview
    • 11.1.6.2. Financial performance
    • 11.1.6.3. Product benchmarking
    • 11.1.6.4. Strategic initiatives
  • 11.1.7. ArisGlobal
    • 11.1.7.1. Overview
    • 11.1.7.2. Financial performance
    • 11.1.7.3. Product benchmarking
    • 11.1.7.4. Strategic initiatives
  • 11.1.8. Capgemini
    • 11.1.8.1. Overview
    • 11.1.8.2. Financial performance
    • 11.1.8.3. Product benchmarking
    • 11.1.8.4. Strategic initiatives
  • 11.1.9. ITClinical
    • 11.1.9.1. Overview
    • 11.1.9.2. Financial performance
    • 11.1.9.3. Products & Services benchmarking
    • 11.1.9.4. Strategic initiatives
  • 11.1.10. ICON plc.
    • 11.1.10.1. Overview
    • 11.1.10.2. Financial performance
    • 11.1.10.3. Product benchmarking
    • 11.1.10.4. Strategic initiatives
  • 11.1.11. TAKE Solutions Limited
    • 11.1.11.1. Overview
    • 11.1.11.2. Financial performance
    • 11.1.11.3. Product benchmarking
    • 11.1.11.4. Strategic initiatives
  • 11.1.12. Parexel International (MA) Corporation
    • 11.1.12.1. Overview
    • 11.1.12.2. Financial performance
    • 11.1.12.3. Product benchmarking
    • 11.1.12.4. Strategic initiatives
  • 11.1.13. Wipro
    • 11.1.13.1. Overview
    • 11.1.13.2. Financial performance
    • 11.1.13.3. Product benchmarking
    • 11.1.13.4. Strategic initiatives
  • 11.1.14. United BioSource LLC
    • 11.1.14.1. Overview
    • 11.1.14.2. Financial performance
    • 11.1.14.3. Product benchmarking
    • 11.1.14.4. Strategic initiatives
  • 11.1.15. BioClinica Inc. (Clario)
    • 11.1.15.1. Overview
    • 11.1.15.2. Financial performance
    • 11.1.15.3. Product benchmarking
    • 11.1.15.4. Strategic initiatives
  • 11.1.16. ClinChoice (formerly FMD K&L)
    • 11.1.16.1. Overview
    • 11.1.16.2. Financial performance
    • 11.1.16.3. Product benchmarking
    • 11.1.16.4. Strategic initiatives

Chapter 12. Winning Strategies

• 12.1. Key Winning / Scoring Criteria
  • 12.1.1. By Categories
    • 12.1.1.1. Pharmaceuticals
    • 12.1.1.2. Biotech companies
    • 12.1.1.3. Medical device companies
  • 12.1.2. Key Vendor Selection Factors
    • 12.1.2.1. By Category
    • 12.1.2.2. BY Company size
      • 12.1.2.2.1.1. Key Takeaways

Chapter 13. Switching Cost Analysis